Skip to main content

Surface Oncology, Inc. (SURF)

NASDAQ: SURF · IEX Real-Time Price · USD
7.60
-0.10 (-1.30%)
After-hours:Oct 15, 2021 7:30 PM EDT
7.70
-0.07 (-0.90%)
At close: Oct 15, 4:00 PM
Market Cap349.98M
Revenue (ttm)89.71M
Net Income (ttm)17.03M
Shares Out43.63M
EPS (ttm)0.40
PE Ratio19.20
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume463,036
Open7.86
Previous Close7.77
Day's Range7.65 - 7.89
52-Week Range4.95 - 14.40
Beta1.65
AnalystsStrong Buy
Price Target16.40 (+113.0%)
Est. Earnings DateNov 9, 2021

About SURF

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protei...

IndustryBiotechnology
IPO DateApr 19, 2018
CEOJ. Jeffrey Goater
Employees51
Stock ExchangeNASDAQ
Ticker SymbolSURF
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for SURF stock is "Strong Buy." The 12-month stock price forecast is 16.40, which is an increase of 112.99% from the latest price.

Price Target
$16.40
(112.99% upside)
Analyst Consensus: Strong Buy

News

Surface Oncology Announces New Randomized Phase 2 Clinical Study Evaluating SRF388 in Patients with First-Line Hepato...

Study initiation underway with first patient dosed by early 2022 Study initiation underway with first patient dosed by early 2022

1 week ago - GlobeNewsWire

Why AstraZeneca and Surface Oncology Rose Today

The pharmaceutical giant reports encouraging results from a late-stage ES-SCLC trial of blockbuster cancer treatment Imfinzi.

Other symbols:AZN
3 weeks ago - The Motley Fool

New Strong Sell Stocks for September 13th

AFMD, DZSI, GMBL, NTRB, and SURF have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2021.

Other symbols:AFMDDZSIGMBLNTRB
1 month ago - Zacks Investment Research

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2021

SRF388, a First-in-Class Anti-IL-27 Antibody, Demonstrates Monotherapy Activity in Ongoing Phase 1 Study; Enrollment Continues for Phase 2 Monotherapy Expansion and Combination Cohorts

2 months ago - GlobeNewsWire

ARK Investment Leans Into Biotech and Telecom Holdings

Catherine Wood (Trades, Portfolio)'s ARK Investment has revealed additions to three biotechnology and telecommunications holdings according to GuruFocus' Real-Time Picks, a Premium feature.

Other symbols:CDXSIRDM
3 months ago - GuruFocus

Surface Oncology Appoints Denice Torres to Board of Directors

Brings 25 years of strategic leadership experience across healthcare Brings 25 years of strategic leadership experience across healthcare

3 months ago - GlobeNewsWire

Surface Oncology's SRF388 Shows Promising Anticancer Activity in Pretreated Patients

Surface Oncology (NASDAQ: SURF) has announced new data from the ongoing Phase 1 studies of SRF388 and SRF617. SRF388 data will be presented at the American Society of Clinical Oncology 2021 Annual Meeting.

4 months ago - Benzinga

Surface Oncology, Roche Team Up to Develop SRF388 Combo Therapy for Liver Cancer

Surface Oncology (NASDAQ: SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC: RHHBY) to evaluate former's SRF388, anti-IL-27 antibody, in combination with Roche's atezoliz...

4 months ago - Benzinga

SRF388, a First-in-Class IL-27 Antibody, Demonstrates Monotherapy Activity in Data Presented at American Society of C...

Preliminary Data for SRF617 Show Good Tolerability and Promise in Combination Approaches

4 months ago - GlobeNewsWire

Surface Oncology to Collaborate with Roche on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, as Part of a ...

CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviro...

4 months ago - GlobeNewsWire

This Is Why Surface Oncology Is a Great Stock to Buy Right Now

It's the right time to be decisive, if you can tolerate uncertainty.

4 months ago - The Motley Fool

Implied Volatility Surging for Surface Oncology (SURF) Stock Options

Investors need to pay close attention to Surface Oncology (SURF) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Could Surface Oncology Be a Millionaire-Maker Stock?

Investors looking for a shot at big gains from this clinical-stage biotech will need to be comfortable with making a speculative buy.

5 months ago - The Motley Fool

Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2021

CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviron...

5 months ago - GlobeNewsWire

Surface Oncology to Present Clinical Updates for SRF388 and SRF617

SRF388 Phase 1 Update to be Presented at American Society for Clinical Oncology Annual Meeting

5 months ago - GlobeNewsWire

Surface Oncology Expands Leadership Team with Key Executive Appointment and Promotions

Henry Rath announced as chief business officer, Alison O'Neill as chief medical officer and Jessica Fees as chief financial officer Henry Rath announced as chief business officer, Alison O'Neill as chie...

5 months ago - GlobeNewsWire

5 Health Care Stocks Trading with Low Price-Earnings Ratios

As of April 21, the GuruFocus All-in-One Screener, a Premium feature, found that the following guru-owned utilities have low price-earnings ratios. While some of them are great value investments, others...

Other symbols:BDSICODXKMDAVMD
5 months ago - GuruFocus

Surface Oncology Named a 2021 Best Places to Work Company by Boston Business Journal

CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today a...

5 months ago - GlobeNewsWire

Surface Oncology Presents Promising Preclinical Data for Lead Immunotherapy Product Candidates at the American Associ...

CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvir...

6 months ago - GlobeNewsWire

Why Surface Oncology Stock Is Soaring Today

The company received an orphan drug designation from the FDA for one of its lead pipeline candidates.

6 months ago - The Motley Fool

Why Surface Oncology Shares Spiked 19% Today

Shares of Surface Oncology Inc. (NASDAQ: SURF), a clinical-stage biopharma company, gained more than 19% in the extended session on Tuesday. What Happened: The spike in shares came after the Cambridge, ...

6 months ago - Benzinga

Why Surface Oncology Is Flying Higher After Hours Today

Its pancreatic cancer drug gets a nod from the FDA.

6 months ago - The Motley Fool

Surface Oncology's SRF617 Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer

CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvir...

6 months ago - GlobeNewsWire

TSMC, BYD, Komatsu, Surface Oncology And 3D Systems — What Cathie Wood's Ark Bought And Sold Today

Every night, Cathie Wood's Ark Investment Management sends out an email listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have been known to cause cer...

Other symbols:DDDTSM
6 months ago - Benzinga

6 Stocks to Play the Value Revival

It's been a long time coming, but the great value comeback appears to be underway.

6 months ago - GuruFocus